Teicoplanin is an antibiotic used to treat endocarditis, osteomyelitis and septic arthritis caused by the methicillin-resistant Staphylococcus aureus (MRSA) bacterium, by inhibiting the synthesis of peptidoglycan in the cell wall [1]. 

Teicoplanin is commercially available. as a solution of glycopeptides whose molecular structure, the mechanism of action, ADME are similar to those of Vancomycin. In this sense, Teicoplanin hydrochloride is available for IV use; the recommended infusion period must be greater than 60 minutes in order to be able to evaluate possible side effects. The dose range in adult patients is 30-45 mg / kg / d administered in at least two doses / day. Current recommendations for serum drug monitoring, through the concentration at steady state, indicate the evaluation of the steady-state dose by taking the sample before the fourth dose. [2]

The minimum trough concentration command is of 10 μg / mL; in patients with more severe infections (for example: endocarditis, osteomyelitis, meningitis and pneumonia due to methicillin-resistant Staphylococcus aureus -MRSA-) basal levels of 15-20 μg / ml are recommended. Difficult can be addressed by administering Teicoplanin in capsules orally or in solution for injection. The recommended dose of Teicoplanin in formulation for oral administration is 125 mg four times a d ì, increasing up to 500 mg four times a day in pationt on chronic polytherapy. [3].

[1] https://doi.org/10.1258/acb.2012.011257

[2] https://doi.org/10.2146/ajhp080434 

[3] Goodman & Gillman – The pharmaceutical basis of therapeutics, 13th edition